MedPath

A single blind, placebo controlled, single center, randomized controlled pilot study to assess if low dose ciprofloxacin can induce antimicrobial resistance in Escherichia coli (HealthyFood Trial)

Phase 1
Conditions
antimicrobial resistance in Escherichia coli
Therapeutic area: Phenomena and Processes [G] - Microbiological Phenomena [G06]
Registration Number
CTIS2023-506205-18-00
Lead Sponsor
Institute Of Tropical Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Able and willing to provide written informed consent, At least 18 years old, Not taking any immunosuppressive agents and not clinically immunocompromised at the time of randomization, For females of childbearing potential only, willingness to practice continuous effective contraception during the study and a negative pregnancy test at the screening visit. Note: In accordance with ICH M3, the following will be classified as ‘effective contraception’: implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, or vasectomized partner.

Exclusion Criteria

Use of any antibiotics in the previous 2 months of Visit 1, Known contra-indications or allergy to ciprofloxacin, Presence of any other condition, that will (likely) require the administration of another antibiotic at the time of randomization, as assessed by the treating physician, Pregnant or breastfeeding, Negative culture for E. coli at Visit 2

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath